| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 11/11/2010 | US20100285022 Anti-rsv g protein antibodies |
| 11/11/2010 | US20100285021 antihemophilic factor monoclonal antibodies comprising an immunoglobulin heavy chain and light chain amino acid sequences, with modified by enzymatic deglycosylation or by site directed mutagenesis, used for treating hemostasis disorders; anticoagulants |
| 11/11/2010 | US20100285020 Leukemic cell cns infiltration controlled by notch-induced chemotaxis |
| 11/11/2010 | US20100285019 Anti-IL-17F Antibodies and Methods of Use Thereof |
| 11/11/2010 | US20100285018 Estrogen receptors and methods of use |
| 11/11/2010 | US20100285017 Matriptase protein and uses thereof |
| 11/11/2010 | US20100285016 PRO34128 nucleic acids |
| 11/11/2010 | US20100285015 Targeting recombinant therapeutics to circulating red blood cells |
| 11/11/2010 | US20100285014 Immunoglobulin fusion proteins |
| 11/11/2010 | US20100285013 Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| 11/11/2010 | US20100285012 Methods and compositions for the treatment of cancers and pathogenic infections |
| 11/11/2010 | US20100285011 High concentration antibody-containing liquid formulation |
| 11/11/2010 | US20100285010 Tumor therapy with an anti-vegf antibody |
| 11/11/2010 | US20100285009 Humanized anti-egfl7 antibodies and methods using same |
| 11/11/2010 | US20100285008 Benzoquinone derivative e3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis |
| 11/11/2010 | US20100285007 Differential diagnosis of b-cell chronic lymphocytic leukemia |
| 11/11/2010 | US20100285006 Compositions of Kinase Inhibitors and Their Use for Treatment of Cancer and Other Diseases Related to Kinases |
| 11/11/2010 | US20100285005 Anti-cxcr4 antibodies |
| 11/11/2010 | US20100285004 Anti-CD38 human antibodies and uses thereof |
| 11/11/2010 | US20100285003 Therapeutic peptides and uses thereof |
| 11/11/2010 | US20100285002 Treatment or prevention of inflammation by targeting cyclin d1 |
| 11/11/2010 | US20100285001 Method and Compositions Related to Synergistic Responses to Oncogenic Mutations |
| 11/11/2010 | US20100285000 Use of vegfr-2 inhibitors for treating metastatic cancer |
| 11/11/2010 | US20100284999 Characterization of the cbir1 antigenic response for diagnosis and treatment of crohn's disease |
| 11/11/2010 | US20100284969 Methods and Compositions for Delivery of Medicaments to the Lungs |
| 11/11/2010 | US20100284963 Growth regulatable recombinant bcg immunogenic compositions |
| 11/11/2010 | US20100284958 BoNT/A Peptides and Methods of Predicting and Reducing Immunoresistance to Botulinum Toxin Therapy |
| 11/11/2010 | US20100284920 Uses of monoclonal antibody 8h9 |
| 11/11/2010 | US20100284918 Protein |
| 11/11/2010 | US20100284916 Antibodies Against Human Cytomegalovirus (HCMV) |
| 11/11/2010 | US20100284915 Genes associated with chemotherapy response and uses thereof |
| 11/11/2010 | US20100284911 Preparations and methods for treating malignancies |
| 11/11/2010 | US20100284910 Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Various Cancers |
| 11/11/2010 | US20100284909 Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins |
| 11/11/2010 | US20100284908 Proteins |
| 11/11/2010 | US20100284907 Treatment of tumors by ablating bone marrow-derived endothelial progenitor cells |
| 11/11/2010 | US20100284906 Internalizing Anti-CD74 Antibodies and Methods of Use |
| 11/11/2010 | US20100284905 Methods and Agents for Inhibiting Tumor Growth by Targeting the SSDNA Replication Intermediate of Tumor Stem Cells |
| 11/11/2010 | CA2838400A1 Humanized anti-egfl7 antibodies and methods using same |
| 11/11/2010 | CA2761203A1 Antibodies against nerve growth factor (ngf) with enhanced in vivo stability |
| 11/11/2010 | CA2760890A1 Anti-cd100 antibodies and methods for using the same |
| 11/11/2010 | CA2760787A1 Combined measles-malaria vaccine |
| 11/11/2010 | CA2760657A1 Method for producing virus from cell culture involving homogenization |
| 11/11/2010 | CA2760246A1 Humanized anti-egfl7 antibodies and methods using same |
| 11/11/2010 | CA2760239A1 Polypeptide derived from enterococcus and its use for vaccination |
| 11/11/2010 | CA2760185A1 Stable high protein concentration formulations of human anti-tnf-alpha antibodies |
| 11/10/2010 | EP2248910A1 Epitope synchronization in antigen presenting cells |
| 11/10/2010 | EP2248900A1 Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use |
| 11/10/2010 | EP2248899A1 NOGO receptor binding protein |
| 11/10/2010 | EP2248831A1 Glycosylated antibodies |
| 11/10/2010 | EP2248830A1 Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection |
| 11/10/2010 | EP2248829A1 Treatment with anti-VEGF antibodies |
| 11/10/2010 | EP2248828A1 Method for treating inflammation |
| 11/10/2010 | EP2248826A1 Antibody directed against pcrv |
| 11/10/2010 | EP2248825A1 Antigen binding fragments of an antibody for use in treating and diagnosing ocular diseases |
| 11/10/2010 | EP2248822A2 Meningococcus adhesins |
| 11/10/2010 | EP2248537A1 Restoration of cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| 11/10/2010 | EP2248535A1 Multicomponent meningococcal vaccine |
| 11/10/2010 | EP2248534A1 Botulinum toxin and the treatment of primary disorders of mood and affect |
| 11/10/2010 | EP2248533A1 Polypeptide derived from enterococcus and its use for vaccination |
| 11/10/2010 | EP2248529A1 Modulation of NKG2D |
| 11/10/2010 | EP2247725A1 Stat3 epitope peptides |
| 11/10/2010 | EP2247620A1 Anti-cd79b antibodies and immunoconjugates and methods of use |
| 11/10/2010 | EP2247618A1 Ferroportin antibodies and methods of use |
| 11/10/2010 | EP2247605A1 Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors |
| 11/10/2010 | EP2247310A1 Compositions and methods for crystallizing antibody fragments |
| 11/10/2010 | EP2247309A2 Tapasin augmentation for enhanced immune response |
| 11/10/2010 | EP2247308A1 Adjuvant compositions comprising poly-ic and a cationic polymer |
| 11/10/2010 | EP2247307A1 Vaccine |
| 11/10/2010 | EP2247306A2 Immunogenic control of tumours and tumour cells |
| 11/10/2010 | EP2247305A1 Stabilized angiopoietin-2 antibodies and uses thereof |
| 11/10/2010 | EP2247304A2 Her2/neu-specific antibodies and methods of using same |
| 11/10/2010 | EP2247289A2 Ophthalmic nsaids as adjuvants |
| 11/10/2010 | EP1556081B1 Recombinant intracellular pathogen immunogenic compositions and methods for use |
| 11/10/2010 | EP1531836B1 Polypeptide cleavage process |
| 11/10/2010 | EP1487483B1 Chimeric infectious dna clones of porcine circovirus and uses thereof |
| 11/10/2010 | EP1411951B2 Enteral compositions for the prevention and/or treatment of sepsis |
| 11/10/2010 | EP1265915B1 Novel compounds |
| 11/10/2010 | CN1816350B Mucosal vaccines with chitosan adjuvant and/or meningococcal antigens |
| 11/10/2010 | CN1798840B Nogo受体结合蛋白 Nogo receptor-binding protein |
| 11/10/2010 | CN1775946B Enhanced virus-mediated DNA transfer |
| 11/10/2010 | CN101883862A Method for production of antibody |
| 11/10/2010 | CN101883858A Simian subfamily E adenoviruses SAdV-39, -25.2, -26, -30, -37, and -38 and uses thereof |
| 11/10/2010 | CN101883856A Influenza virus-like particles (VLPs) comprising hemagglutinin produced within a plant |
| 11/10/2010 | CN101883793A Anti-idiotypic antibodies which neutralise the inhibitory activity of an inhibitory antibody directed against the C1 domain of factor VIII |
| 11/10/2010 | CN101883792A New antibodies specific of the beta-amyloid peptides and their uses as diagnostic agents or drugs |
| 11/10/2010 | CN101883791A Humanized antibody |
| 11/10/2010 | CN101883790A Use of anti-amyloid beta antibody in ocular diseases |
| 11/10/2010 | CN101883789A Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof |
| 11/10/2010 | CN101883786A Compositions of humanized NOTCH fusion proteins and methods of treatment |
| 11/10/2010 | CN101883588A High concentration antibody-containing liquid formulation |
| 11/10/2010 | CN101883587A Imageable rodent model of asthma |
| 11/10/2010 | CN101883586A Methods of treating neurological autoimmune disorders with cyclophosphamide |
| 11/10/2010 | CN101883585A A powerful vaccine composition comprising a lipopeptide and poly I:C as an adjuvant |
| 11/10/2010 | CN101883584A Allergen desensitization method |
| 11/10/2010 | CN101883583A Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
| 11/10/2010 | CN101883582A Compositions for eliciting an immune response against mycobacterium avium subspecies paratuberculosis |
| 11/10/2010 | CN101883581A Mycoplasma hyopneumoniae avirulent adjuvanted live vaccine |
| 11/10/2010 | CN101883578A Use of VEGFR-2 inhibitors for treating metastatic cancer |
| 11/10/2010 | CN101883560A Method and compositions for cutaneous immunisation |